tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Sanofi (FR:SAN)
:SAN
France Market
SAN
Sanofi
Overview
Analyst Forecasts
AI Stock Analysis
Popular
Dividends
Earnings
Financials
Statistics
New
Technical Analysis
Historical Prices
New
News & Insights
Chart
RESEARCH TOOLS
Top Analyst Stocks
Top Smart Score Stocks
Stock Screener
reports
Advertisement

Sanofi (SAN) Stock News & Sentiment

Compare
238 Followers
Sanofi’s Amlitelimab: Buy Rating Amid Challenges and Opportunities in Atopic Dermatitis Market
Premium
Ratings
Sanofi’s Amlitelimab: Buy Rating Amid Challenges and Opportunities in Atopic Dermatitis Market
9d ago
SNY
Sanofi’s Promising Ulcerative Colitis Study: What Investors Need to Know
Premium
Company Announcements
Sanofi’s Promising Ulcerative Colitis Study: What Investors Need to Know
9d ago
SNYNF
Sanofi’s Promising Crohn’s Disease Study: What Investors Need to Know
Premium
Company Announcements
Sanofi’s Promising Crohn’s Disease Study: What Investors Need to Know
9d ago
SNYNF
Sanofi’s Amlitelimab Study: A Potential Game-Changer for Atopic Dermatitis
Premium
Company Announcements
Sanofi’s Amlitelimab Study: A Potential Game-Changer for Atopic Dermatitis
9d ago
SNYNF
Sanofi’s Promising Phase 3 Study on Frexalimab for Multiple Sclerosis
Premium
Company Announcements
Sanofi’s Promising Phase 3 Study on Frexalimab for Multiple Sclerosis
9d ago
SNYNF
Sanofi’s Frexalimab Study: A Potential Game-Changer for Multiple Sclerosis Treatment
Premium
Company Announcements
Sanofi’s Frexalimab Study: A Potential Game-Changer for Multiple Sclerosis Treatment
9d ago
SNYNF
Sanofi’s New Study on Amlitelimab Delivery: What Investors Need to Know
Premium
Company Announcements
Sanofi’s New Study on Amlitelimab Delivery: What Investors Need to Know
9d ago
SNYNF
More FR:SAN News >

SAN News on the Web

Should Investors Reassess Sanofi After 14% Drop and Fresh Migraine Drug Approval?
Simply Wall St
Neutral
Sanofi: FDA Grants Fast Track Designation For SAR402663
rttnews
Neutral
Sanofi : Tzield Approved In China To Delay Stage 3 Type 1 Diabetes In Pediatric And Adult Patients
rttnews
Neutral
UBS Sticks to Its Buy Rating for Sanofi (SNYNF)
TipRanks News
Neutral
Here are Monday's biggest analyst calls: Nvidia, Apple, Tesla, Palantir, Oracle, Chewy, Roblox, Alphabet & more
CNBC
Neutral
Positive Report for Sanofi (SNYNF) from Morgan Stanley
TipRanks News
Neutral
Sanofi’s Promising Crohn’s Disease Study: What Investors Need to Know
TipRanks News
Neutral
Sanofi’s Amlitelimab Study: A Potential Game-Changer for Atopic Dermatitis
TipRanks News
Neutral

News Score - Last 7 Days

Neutral
FR:SAN
Sector Average
Media Buzz
This Week3 articles
Weekly Average5.5 articles
News Sentiment
This Week50%
Sector Average56%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is FR:SAN’s Media Buzz Sentiment?
3 articles about FR:SAN were published this week. In an average week, 5.5 articles are published.
    What is FR:SAN’s weekly average amount of articles?
    In an average week, 5.5 articles about FR:SAN are published.
      What is FR:SAN’s News Sentiment?
      50% of articles about FR:SAN were positive this week, compared to its sector average of 56%.
        Healthcare Stocks that are Trending in the News
        OMCLOmnicell
        GLUEMonte Rosa Therapeutics
        THCTenet Healthcare
        TVTXTravere Therapeutics
        CHEKCheck-Cap
        Showing the stocks with the most bullish news sentiment over the past week

        Become an Expert with TipRanks Premium

        What am I Missing?
        Make informed decisions based on Top Analysts' activity
        Know what industry insiders are buying
        Get actionable alerts from top Wall Street Analysts
        Find out before anyone else which stock is going to shoot up
        Get powerful stock screeners & detailed portfolio analysis
        Subscribe NowSee Plans & Pricing